Year-end Sale % OFF 
Abstract
Introduction: A major therapeutic challenge in the salvage of Group D retinoblastoma eyes is the poor response of vitreous seeds to intravenous chemotherapy. The novel use of intravitreal melphalan has greatly impacted the salvage of such eyes; however, concerns regarding its safety and toxicity still exist, particularly in dark-eyed children. This study aims to evaluate our experience and determine the visual and anatomical outcomes of intravitreal melphalan in group D retinoblastoma with resistant vitreous seeds.Method: All patients, from August 2018 to February 2020, with group D retinoblastoma harboring vitreous seeds refractory to first-line chemo reduction regimen with vincristine, etoposide, and carboplatin for six cycles plus local consolidation with thermotherapy or cryotherapy were evaluated. Fifteen eyes of 15 patients that fulfilled the eligibility criteria and received intravitreal melphalan were retrospectively reviewed for demographics, iris color, treatments offered, seed inactivation, globe survival, visual acuity, and complications.Result: Mean age at presentation was 22 months for bilateral disease and 36 months for unilateral disease. A total of 77 injections were administered (mean, five injections per eye) with doses ranging from 20 µg to 30 µg. Complete seed control was seen in 13 of 15 (87%) eyes, and globe salvage was possible in 11 of 15 (73%) eyes. Eyes with macular tumor had visual acuity ranging from 6/36 (0.8) to 6/60 (1.0). SIx of eight eyes (75%) with extra macular tumors had vision 0.4 or better.Conclusion: Intravitreal melphalan seems like a promising treatment modality in group D retinoblastoma with resistant vitreous seeds having dark eyes. Amblyopia therapy may play an important role in attaining maximal visual benefits in these children.
Highlights
A major therapeutic challenge in the salvage of Group D retinoblastoma eyes is the poor response of vitreous seeds to intravenous chemotherapy
International Intraocular Retinoblastoma Classification (IIRC) of Group D retinoblastoma [2] corresponds to Reese Ellsworth group V which is labeled to carry the worst prognosis for globe salvage [3]
We reviewed our experience with intravitreal melphalan in eyes classified as group D retinoblastoma (International Intraocular Retinoblastoma Classification [2]) for resistant vitreous seeds to assess anatomical and visual benefits in our local population over 18 months
Summary
A major therapeutic challenge in the salvage of Group D retinoblastoma eyes is the poor response of vitreous seeds to intravenous chemotherapy. The use of a chemotherapeutic agent targeted into the vitreous cavity was first encouraged by Suzuki et al, who concluded an eye salvage rate of 51% [5]; retinoblastoma cells have unstable chromosomes and are harvested at their highest mitotic index [6], causing them to infiltrate rapidly [7]. Intravitreal chemotherapy did not gain acceptance until Munier et al developed an anti-reflux technique with needle track sterilization [8]. This novel method has shown to have minimal chances of extraocular seeding of tumor cells and very promising outcomes in globe salvage with advanced disease
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
